When comparing the TROP2 expression profile in the tumor samples from the patients, we observed an apparent discrepancy between the relatively small increase in TROP2 mRNA expression in LGD, HGD, and CRC tumors and the relatively strong positivity of TROP2 protein/antigen staining in the same tumor type (Figure 1). This evidence concerns the gene TACSTD2 and colorectal carcinoma.